A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test.
Adult
Biomarkers
/ blood
Blood Glucose
/ metabolism
Blood Pressure
Body Mass Index
China
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Dietary Fats
/ administration & dosage
Dyslipidemias
/ blood
Female
Humans
Liver Function Tests
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ blood
Postprandial Period
Triglycerides
/ blood
Clinical study
Dyslipidemia
Nonalcoholic fatty liver disease
Oral fat tolerance test
Postprandial lipidemia
Triglyceride
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
25 May 2021
25 May 2021
Historique:
received:
15
02
2021
accepted:
18
05
2021
entrez:
26
5
2021
pubmed:
27
5
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases worldwide. Triglyceride (TG) accumulation is central to NAFLD development. People now spend most of their day in the postprandial state, and the measurement of postprandial blood lipid concentration can make up for the lack of simple detection of fasting blood lipids. Postprandial triglyceride (PTG) is commonly used as a surrogate for postprandial blood lipid concentrations, and many studies have shown that PTG is a risk factor for NAFLD. The aim of the present study was to investigate the relationship between PTG concentration during oral fat tolerance testing (OFTT) and NAFLD. A total of 472 Chinese adults, aged 25 to 65 years, were enrolled in the study. All the participants underwent OFTT. The serum concentrations of TG and other lipids were measured, and their relationships with NAFLD were analyzed. Of the 472 participants, 155 were diagnosed with NAFLD. The fasting and postprandial TG concentrations of the participants with NAFLD were higher than those of healthy participants (P < 0.05). The TG concentrations of the healthy participants peaked 4 h postprandially, whereas those of the participants with NAFLD peaked 6 h postprandially and reached higher peak values. Postprandial TG concentration was significantly associated with a higher risk of NAFLD. High PTG is positively related to a higher risk of NAFLD, and the PTG concentrations of patients with NAFLD are higher than in healthy individuals, with a delayed peak. Therefore, 4-h PTG may represent a potential marker of NAFLD. ChiCTR1800019514 .
Sections du résumé
BACKGROUND
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases worldwide. Triglyceride (TG) accumulation is central to NAFLD development. People now spend most of their day in the postprandial state, and the measurement of postprandial blood lipid concentration can make up for the lack of simple detection of fasting blood lipids. Postprandial triglyceride (PTG) is commonly used as a surrogate for postprandial blood lipid concentrations, and many studies have shown that PTG is a risk factor for NAFLD. The aim of the present study was to investigate the relationship between PTG concentration during oral fat tolerance testing (OFTT) and NAFLD.
METHODS
METHODS
A total of 472 Chinese adults, aged 25 to 65 years, were enrolled in the study. All the participants underwent OFTT. The serum concentrations of TG and other lipids were measured, and their relationships with NAFLD were analyzed.
RESULTS
RESULTS
Of the 472 participants, 155 were diagnosed with NAFLD. The fasting and postprandial TG concentrations of the participants with NAFLD were higher than those of healthy participants (P < 0.05). The TG concentrations of the healthy participants peaked 4 h postprandially, whereas those of the participants with NAFLD peaked 6 h postprandially and reached higher peak values. Postprandial TG concentration was significantly associated with a higher risk of NAFLD.
CONCLUSIONS
CONCLUSIONS
High PTG is positively related to a higher risk of NAFLD, and the PTG concentrations of patients with NAFLD are higher than in healthy individuals, with a delayed peak. Therefore, 4-h PTG may represent a potential marker of NAFLD.
TRIAL REGISTRATION
BACKGROUND
ChiCTR1800019514 .
Identifiants
pubmed: 34034748
doi: 10.1186/s12944-021-01483-z
pii: 10.1186/s12944-021-01483-z
pmc: PMC8152134
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Dietary Fats
0
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Subventions
Organisme : Hebei Province Science and Technology Support Program
ID : zh2018001
Références
J Clin Lipidol. 2016 Sep-Oct;10(5):1163-71
pubmed: 27678433
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Food Funct. 2020 Apr 1;11(4):3191-3200
pubmed: 32211679
Int J Gen Med. 2018 Jul 18;11:313-322
pubmed: 30050317
Curr Vasc Pharmacol. 2019;17(5):538-540
pubmed: 31418346
J Pediatr (Rio J). 2018 May - Jun;94(3):308-312
pubmed: 28881179
Atherosclerosis. 2014 Jan;232(1):99-109
pubmed: 24401223
Hypertension. 2020 Feb;75(2):275-284
pubmed: 31865799
Curr Vasc Pharmacol. 2018;16(4):385-392
pubmed: 28552072
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Lipids Health Dis. 2018 Jul 18;17(1):156
pubmed: 30021651
Arq Gastroenterol. 2019 Sep 30;56(3):270-275
pubmed: 31633724
J Hepatol. 2010 Aug;53(2):372-84
pubmed: 20494470
Clin Chim Acta. 2019 Mar;490:147-153
pubmed: 30615853
J Am Heart Assoc. 2019 Dec 17;8(24):e013713
pubmed: 31818211
Circ Res. 2014 Jan 3;114(1):171-82
pubmed: 24385510
BMC Res Notes. 2020 Apr 16;13(1):218
pubmed: 32299490
Eur Heart J. 2016 Jul 01;37(25):1944-58
pubmed: 27122601
Eur J Clin Nutr. 2020 Jul;74(7):1084-1090
pubmed: 31804627
Dig Liver Dis. 2002 Mar;34(3):204-11
pubmed: 11990393
Front Public Health. 2020 Jul 02;8:220
pubmed: 32714888
Lipids. 2017 Aug;52(8):675-686
pubmed: 28653085
J Hepatol. 2018 Feb;68(2):326-334
pubmed: 29122695
J Clin Endocrinol Metab. 2001 Oct;86(10):4615-7
pubmed: 11600512
Metabolism. 2016 Aug;65(8):1038-48
pubmed: 26823198
Ann Hepatol. 2020 Jul - Aug;19(4):359-366
pubmed: 32349939
J Pediatr Endocrinol Metab. 2020 Feb 25;33(2):233-239
pubmed: 31804963
Aliment Pharmacol Ther. 2018 Oct;48(7):696-703
pubmed: 30136293
Metabolism. 2016 Aug;65(8):1017-25
pubmed: 26997539
Curr Vasc Pharmacol. 2011 May;9(3):271-80
pubmed: 21314631
Indian J Endocrinol Metab. 2013 Jul;17(4):665-71
pubmed: 23961483
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):195-203
pubmed: 29804393
J Gastroenterol Hepatol. 2007 Dec;22(12):2118-23
pubmed: 18031368
Mol Nutr Food Res. 2020 May;64(9):e1901035
pubmed: 32223057
Diabetes Metab Syndr. 2019 May - Jun;13(3):1917-1921
pubmed: 31235115
Am J Gastroenterol. 2018 Nov;113(11):1649-1659
pubmed: 29880964
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418